Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 703067
                    [Title] => Roche's drug receives broader EU label  for women with metastatic breast cancer
                    [Summary] => 
BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
                    [DatePublished] => 2011-07-07 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 564068
                    [Title] => Elderly colorectal cancer patients live cancer-free longer
                    [Summary] => 
The results of the international phase III study NO16968 (XELOXA), an open-label, randomized trial of Xelox (oral capecitabine in combination with intravenous oxaliplatin) versus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for patients with stage III colon cancer who have undergone surgery, showed the superiority of Xelox versus 5-FU/LV in terms of disease-free survival (DFS).
                    [DatePublished] => 2010-04-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 293346
                    [Title] => Study offers new hope for colon cancer cases
                    [Summary] => Colon cancer is a leading cause of cancer deaths in both men and women, occurring most frequently in men and women older than 50.


Colon cancer is most common in people who smoke, eat a high-fat diet, and have a family history of colorectal cancer. However, majority of colon cancers occur in people older than 50 with no known risk factors other than age. 


                    [DatePublished] => 2005-08-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 284181
                    [Title] => Oral chemotherapy: A unique treatment option
                    [Summary] => Recent data further strengthen the wealth of evidence showing that capecitabine, an innovative oral chemotherapy, should replace the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV) for colon cancer patients in the adjuvant (post-surgery) setting. 


In March 2005, Roche received approval from European authorities for capecitabine to be used as a post-surgery treatment in colon cancer patients.  


                    [DatePublished] => 2005-06-30 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 275629
                    [Title] => Adjuvant treatment for colon cancer OK’d
                    [Summary] => European authorities recently approved capecitabine, an innovative oral chemotherapy, as an adjuvant treatment (post-surgery) for colon cancer. 


The drug has been shown to prolong cancer-free survival with less serious side effects compared to standard current treatment. 


Adjuvant chemotherapy is a standard treatment approach for stage III colon cancer to destroy cancer cells remaining in the body after the tumor has been surgically removed.


                    [DatePublished] => 2005-04-28 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

CAPECITABINE

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 703067
                    [Title] => Roche's drug receives broader EU label  for women with metastatic breast cancer
                    [Summary] => 
BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
                    [DatePublished] => 2011-07-07 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 564068
                    [Title] => Elderly colorectal cancer patients live cancer-free longer
                    [Summary] => 
The results of the international phase III study NO16968 (XELOXA), an open-label, randomized trial of Xelox (oral capecitabine in combination with intravenous oxaliplatin) versus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for patients with stage III colon cancer who have undergone surgery, showed the superiority of Xelox versus 5-FU/LV in terms of disease-free survival (DFS).
                    [DatePublished] => 2010-04-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 293346
                    [Title] => Study offers new hope for colon cancer cases
                    [Summary] => Colon cancer is a leading cause of cancer deaths in both men and women, occurring most frequently in men and women older than 50.


Colon cancer is most common in people who smoke, eat a high-fat diet, and have a family history of colorectal cancer. However, majority of colon cancers occur in people older than 50 with no known risk factors other than age. 


                    [DatePublished] => 2005-08-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 284181
                    [Title] => Oral chemotherapy: A unique treatment option
                    [Summary] => Recent data further strengthen the wealth of evidence showing that capecitabine, an innovative oral chemotherapy, should replace the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV) for colon cancer patients in the adjuvant (post-surgery) setting. 


In March 2005, Roche received approval from European authorities for capecitabine to be used as a post-surgery treatment in colon cancer patients.  


                    [DatePublished] => 2005-06-30 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 275629
                    [Title] => Adjuvant treatment for colon cancer OK’d
                    [Summary] => European authorities recently approved capecitabine, an innovative oral chemotherapy, as an adjuvant treatment (post-surgery) for colon cancer. 


The drug has been shown to prolong cancer-free survival with less serious side effects compared to standard current treatment. 


Adjuvant chemotherapy is a standard treatment approach for stage III colon cancer to destroy cancer cells remaining in the body after the tumor has been surgically removed.


                    [DatePublished] => 2005-04-28 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche's drug receives broader EU label for women with metastatic breast cancer

July 7, 2011 - 12:00am

BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.

Science and Environment

Elderly colorectal cancer patients live cancer-free longer

April 8, 2010 - 12:00am

The results of the international phase III study NO16968 (XELOXA), an open-label, randomized trial of Xelox (oral capecitabine in combination with intravenous oxaliplatin) versus 5-fluorouracil/leucovorin (5-FU/LV)...

Science and Environment

Study offers new hope for colon cancer cases

August 25, 2005 - 12:00am

Colon cancer is a leading cause of cancer deaths in both men and women, occurring most frequently in men and women older than 50. Colon cancer is most common in people who smoke, eat a high-fat diet, and have a...

Science and Environment

Oral chemotherapy: A unique treatment option

June 30, 2005 - 12:00am

Recent data further strengthen the wealth of evidence showing that capecitabine, an innovative oral chemotherapy, should replace the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV)...

Science and Environment

Adjuvant treatment for colon cancer OK’d

April 28, 2005 - 12:00am

European authorities recently approved capecitabine, an innovative oral chemotherapy, as an adjuvant treatment (post-surgery) for colon cancer. The drug has been shown to prolong cancer-free survival with less...

Science and Environment